FDA Approved: ZARXIO — Original Application (Sandoz Inc.)

View source ↗

Summary

FDA approved Zarxio (filgrastim-sndz) from Sandoz as a biosimilar to filgrastim. It is indicated to reduce the duration of neutropenia in patients with cancer r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia Due to Cancer Chemotherapy

Drugs mentioned

• ZARXIO (FILGRASTIM-SNDZ)

Snippet

ORIG AP for ZARXIO (FILGRASTIM-SNDZ)